Topic: Diovan
Diversified healthcare giant Novartis (NYSE:NVS) reported impressive 2011 results in January 2012. These strong trends are not projected to carry...
Novartis AG is bracing for lower profitability this year as key products like top-selling blood pressure drug Diovan face competition from cheaper...
Novartis (NVS) is one of the largest and most diversified health care companies in the world.. Revenue Growth: 9%Income Growth: 10%Cash Flow ...
0 . Novartis AG's first-quarter sales and profit surpassed analyst forecasts on higher revenue from a generic blood thinner and the Gleevec cancer...
ZURICH - Novartis AG (NVS) Thursday said its cancer drug Afinitor and its lung medicine Onbrez Breezhaler showed positive results in recent...
Generic Opportunities Arising for the Blockbuster Antihypertensive, Diovan (Valsartan) . . GenericsWeb, a leader in established pharmaceutical...
By Sheena Lee. Swiss pharmaceutical company Novartis (NOV) faces expiring patents on some of its highest revenue generating products, including the...
After an endocrinologist in Walnut Creek, California, diagnosed a middle-aged male patient with hypertension, she put him on a regimen of Diovan, a medication that lowers blood pressure, and sent him home with supplies: Eric Topol, director of the Scripps Translational Science ...
Valsartan is an angiotensin II receptor antagonist (more commonly called an " Valsartan is marketed by Novartis under the trade name Diovan . In 2005, Diovan was prescribed more than 12 million times in the United States . Diovan HCT contains a combination of valsartan ...
Diovan is an antihypertensive drug that can be given alone or in combination with other medications for the treatment of hypertension. However, unlike ACE inhibitors, Diovan (valsartan) does not affect the production of angiotensin II from angiotensin I. Diovan (valsartan) merely acts ...
![NEW! Hard Electro Mix [2011] by DJ DIOVAN](http://i.ytimg.com/vi/RP8-jQn_4Og/0.jpg)
